🔔 FDA PDUFA Update…
🚨 1 AdCom & 3 PDUFA decisions this week:
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory syncytial virus
‣ PDUFA date: 6/7/24 (sBLA)
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory syncytial virus
‣ PDUFA date: 6/7/24 (sBLA)
$Geron(GERN.US$ : Approved 6/6 🎉
⇨ RYTELO™ (imetelstat)
‣ lower-risk MDS w/ transfusion-dependent anemia 🩸
‣ PDUFA date: 6/16/24 (NDA)
⇨ RYTELO™ (imetelstat)
‣ lower-risk MDS w/ transfusion-dependent anemia 🩸
‣ PDUFA date: 6/16/24 (NDA)
![🔔 FDA PDUFA Update…](https://ussnsimg.moomoo.com/sns_client_feed/70042970/20240611/3d36434ca49349e79e791a53dcf5f4b3.png/big?area=100&is_public=true)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
SanjBot : nothing like a few gallstones to make you feel alive.